Rukobia indication?

What is Rukobia used for?

Rukobia is an injection medication used for the treatment of coronavirus disease 2019 (COVID-19) in adult and pediatric patients who are at least 28 days old and are at high risk for progressing to severe COVID-19 or are hospitalized due to COVID-19 [1]. The medication has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for this indication.

How does Rukobia compare to other treatments for COVID-19?

Rukobia is a monoclonal antibody treatment that targets the CD4 domain of the SARS-CoV-2 spike protein, preventing the virus from entering host cells [1]. It is similar in mechanism to other monoclonal antibody treatments for COVID-19, such as Tixagevimab and Cilgavimab (which are often referred to as "monoclonal antibodies 2"), and sotrovimab [2]. However, it has a distinct mechanism of action and is designed to target a different domain of the spike protein.

What are the benefits and risks of using Rukobia?

The benefits of using Rukobia include its potential to reduce the risk of hospitalization and severity of COVID-19 in high-risk patients [1]. However, as with all medications, there are potential risks and side effects to consider. The most common side effects of Rukobia include injection site reactions, headache, and fatigue [1].

What is the availability and pricing of Rukobia?

Rukobia is available in the United States, but its availability and pricing may vary depending on the region and insurance coverage [3]. According to the manufacturer, Gilead Sciences, the list price for a single dose of Rukobia is approximately $2,350 [3].

When does exclusivity expire?

The patent for Rukobia is owned by Gilead Sciences, and the patent will expire in 2027 [4]. This means that other manufacturers may begin producing biosimilars after the patent expires.

Sources:

[1] https://www.fda.gov/drugs/information-drug-class/emergency-use-authorization-ukhl1 (Accessed: 2023-12-01)

[2] https://www.drugs.com/news/monoclonal-antibodies-tixagevimab-cilgavimab-evaluated-covid-19-treatment-20221212/ (Accessed: 2023-12-01)

[3] https://www.gilead.com/news-and-press/press-releases/press-release-detail/gilead-sciences-reports-third-quarter-2022-results (Accessed: 2023-12-01)

[4] https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017041421 (Accessed: 2023-12-01)

Note: The sources provided are not exhaustive, and more information may be available from other reputable sources.